Form 4: Cargo Therapeutics Executive Granted Stock Options

Shishir Gadam, Chief Technical Officer of Cargo Therapeutics, was granted stock options for 100,000 shares on March 1, 2024, according to a Form 4 filing.

Summary

• A Form 4 filing reveals that Shishir Gadam, the Chief Technical Officer of Cargo Therapeutics, Inc., was granted stock options on March 1, 2024.
• The options grant covers 100,000 shares of Cargo Therapeutics' common stock.
• The exercise price of the stock options is $25.07 per share.
• The options vest monthly, with 1/48th of the shares vesting each month starting from January 1, 2024.
• The options will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
• The expiration date for the options is February 28, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice, but it indicates confidence in the company's future and incentivizes the executive.

Positives

• The granting of stock options to a key executive like the CTO suggests the company is incentivizing leadership to drive long-term growth.
• The vesting schedule encourages the executive's continued commitment to the company over the next four years.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the stock option grant suggests an expectation of continued growth and value creation.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders by incentivizing them to increase the company's stock price.

Comparison to Industry Standards

• Stock option grants are a standard practice in the biotech industry to attract and retain talent.
• Companies like Amgen, Gilead, and Biogen routinely use stock options as part of their compensation packages for executives.
• The vesting schedule of 1/48th monthly is a fairly standard vesting schedule.
• The exercise price is likely based on the fair market value of the stock at the time of the grant, which is a common practice.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns management's interests with increasing shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates